Burning Mouth Syndrome - New Diagnostic Criteria and Treatment
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The first part of this study is to optimize diagnostic criteria for BMS, i.e. not a clinical
trial, and will not be covered in this application.
The second part will compare topical treatment with clonazepam, capsaicin and placebo in a
n-of-1 study design regarding effects of pain, pain-related disability, somatosensory changes
in the trigeminal nerve and patient experience in patients with primary BMS or other oral
mucosal pain. The patients will be treated for two weeks with each drug, with a one-week
wash-out period in between. After the last washed-out period, the patients will be able to
chose the treatment that they prefer the most and continue with that treatment during 6
months.